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Abstract
The aim of this study was to compare the impact of dietary supplementation with a Bifidobacterium breve strain together
with linoleic acid & a-linolenic acid, for 7 weeks, on colonic sensitivity and fatty acid metabolism in rats. Maternally
separated and non-maternally separated Sprague Dawley rats (n = 15) were orally gavaged with either B. breve DPC6330
(109 microorganisms/day) alone or in combination with 0.5% (w/w) linoleic acid & 0.5% (w/w) a-linolenic acid, daily for 7
weeks and compared with trehalose and bovine serum albumin. Tissue fatty acid composition was assessed by gas-liquid
chromatography and visceral hypersensitivity was assessed by colorectal distension. Significant differences in the fatty acid
profiles of the non-separated controls and maternally separated controls were observed for a-linolenic acid and arachidonic
acid in the liver, oleic acid and eicosenoic acid (c11) in adipose tissue, and for palmitoleic acid and docosahexaenoic acid in
serum (p,0.05). Administration of B. breve DPC6330 to MS rats significantly increased palmitoleic acid, arachidonic acid and
docosahexaenoic acid in the liver, eicosenoic acid (c11) in adipose tissue and palmitoleic acid in the prefrontal cortex
(p,0.05), whereas feeding B. breve DPC6330 to non separated rats significantly increased eicosapentaenoic acid and
docosapentaenoic acid in serum (p,0.05) compared with the NS un-supplemented controls. Administration of B. breve
DPC6330 in combination with linoleic acid and a-linolenic acid to maternally separated rats significantly increased
docosapentaenoic acid in the serum (p,0.01) and a-linolenic acid in adipose tissue (p,0.001), whereas feeding B. breve
DPC6330 with fatty acid supplementation to non-separated rats significantly increased liver and serum docosapentaenoic
acid (p,0.05), and a-linolenic acid in adipose tissue (p,0.001). B. breve DPC6330 influenced host fatty acid metabolism.
Administration of B. breve DPC6330 to maternally separated rats significantly modified the palmitoleic acid, arachidonic acid
and docosahexaenoic acid contents in tissues. The effect was not observed in non-separated animals.
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Introduction
The microbiota of the gastrointestinal (GI) tract contains
trillions of microorganisms performing vital functions for the host
[1,2]. The GI microbiota has a significant influence on human
health and has been implicated in a number of disease states,
including obesity and inflammatory bowel diseases [3,4]. Of
particular interest among the gut microbiota are the commensal
group, Bifidobacterium, which constitute an estimated 3% of the
intestinal microbiota of adults [5,6] and can dominate and
outnumber all other bacterial groups and species in newborns
[7,8,9]. They are considered, along with lactobacilli, to be among
the most important health promoting bacteria in humans, as well
as being among the most studied probiotics [10,11]. Proposed
health benefits include reductions of diarrhoea, rotavirus infection,
and atopic dermatitis, amelioration of lactose intolerance, and
modulation of the immune system [12,13,14]. One further
proposed health benefit is alleviation of the symptoms of irritable
bowel syndrome (IBS), thus extensive research has been conducted
on the use of bifidobacteria and lactic acid bacteria in the
treatment of this disorder [15,16,17].
IBS is a common functional disorder of the human GI tract,
characterised by abdominal pain and discomfort, and is generally
viewed as a disorder of the brain-gut axis [18,19]. It is one of the
most common reasons for patient visits to gastroenterologists and
has an estimated worldwide prevalence of 10–15% [19]. An
inability to cope with stress has been implicated in the
development and aggravation of IBS, in addition to immune
activation, alterations in the gut microbiota and visceral hyper-
sensitivity [20,21,22]. One such stress is early life maternal
separation, which has been implicated in alterations in the
development of the central nervous system [23,24,25]. Early life
stress in humans predisposes individuals to stress related disorders
such as IBS later in life [26,27]. This can be readily modelled in
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animals using the maternal separation model whereby brief
separation of rat pups from the mother triggering long-term
changes in colonic sensitivity to rectal distension, which manifests
itself as an increase in visceral pain, thereby mimicking the clinical
features of IBS [25,28]. It has also been reported that the v-6: v-3
fatty acid ratio in maternally separated rodents was significantly
increased when compared with non-separated rodents [29]. For
example, arachidonic acid (C20:4n-6), a fatty acid found in
elevated concentrations in the plasma of IBS patients, was
significantly elevated in plasma of separated animals compared
with control rodents [29]. In addition to altered fatty acid ratio, it
has also been reported that feeding B. infantis reverses behavioural
defects in maternally separated rats [30].
Essential fatty acids are important components of all neuronal
membranes and perform vital roles in regulating the activity of
both ionotropic and metabotropic receptors [31]. a-Linolenic acid
(ALA, C18:3n-3), a precursor of v-3 series fatty acids, and cis-
linoleic acid (LA, C18:2n-6), a precursor of v-6 series fatty acids
are essential fatty acids in humans [32]. ALA is converted to
eicosapentaenoic acid (EPA, C20:5n-3) which in turn is converted
to the 3-series of prostaglandins and docosahexaenoic acid (DHA,
C22:6n-3). LA is converted to c-linolenic acid (GLA, C18:3n-6)
which can be metabolized to dihomo-GLA (C20:3n-6) and
arachidonic acid, precursors of the 1- and 2- series of prostaglan-
dins. Indeed, it has been reported that the aforementioned fatty
acids can influence pro-inflammatory cytokine production, with
EPA and DHA inhibiting the production of tumour necrosis
factor-a (TNF-a), interleukin (IL)-6 and IL-2, while arachidonic
acid increases the production of pro-inflammatory eicosanoids and
consequently pro-inflammatory cytokines [33].
The v-6: v-3 fatty acid ratio is an important factor in health,
with an ideal diet incorporating a dietary ratio of 4:1 v-6 and v-3,
respectively [34]. Most Western diets have a 10:1 ratio in favour of
v-6 polyunsaturated fatty acids, predominantly due to increased
LA consumption [35], and high levels of coronary artery disease,
some cancers and possibly depression have been attributed to this
imbalance [36,37]. Furthermore, patients suffering from IBS have
been reported to have elevated plasma arachidonic acid, in
addition to elevated plasma IL-6 [38,39,40], and more recently
lower levels of arachidonic acid have been detected in the serum of
IBS patients [41].
A possible way of altering the v-6: v-3 dietary imbalance is by
modulation with conjugated linoleic acid (CLA), a natural
component of ruminant milk and tissue fat. It comprises of a
mixture of positional and geometric conjugated isomers of LA and
has a number of proposed health benefits, most notably anti-
carcinogenic, immuno-modulatory, anti-obesity and anti-athero-
sclerotic activities [42,43,44,45]. It has been reported that CLA
can induce essential fatty acid redistribution in mice [46].
Alterations in DHA and arachidonic acid levels were observed
in some organs. For example, the DHA content of heart tissue was
reduced by 25%, while in the spleen, DHA content increased and
arachidonic acid content was reduced [46]. Furthermore, feeding
CLA producing bifidobacteria can influence the fatty acid
composition of murine tissues [47,48]. It has been reported that
the CLA-producing bacterium, B. breve NCIMB702258, converts
LA to CLA in the murine gut, resulting in significantly elevated c9,
t11 CLA in the liver [47]. Significantly higher concentrations of
EPA, DHA, dihomo-c-linolenic acid (20:3n-6) and stearic acid
(18:0) were also reported in the colon, as well as significantly
higher concentrations of stearidonic acid (18:4n-3) in liver and
DHA in brain [47,49].
The aim of the current study was to examine the impact of
dietary intervention with B. breve DPC6330 together with 0.5%
(w/w) LA & 0.5% (w/w) ALA on visceral sensitivity and fatty acid
metabolism in maternally separated adult rats.
Materials and Methods
Animals
Two groups, maternally separated (MS) (n = 45) and non-
separated (NS) (n = 45), of Sprague Dawley (Harlan Ltd. Briester,
UK) rat pups were used in this study. The pups were housed with
their mothers in plastic cages in a temperature controlled room on
12 h light/dark cycle. Each of the two groups were subsequently
divided into 3 groups (n = 15) (6615) and assigned to one of the
following dietary treatments: One group received 0.5% (w/w) LA
plus 0.5% (w/w) ALA (triglyceride bound form; Larodan Fine
Chemicals, Malmo, Sweden) of their diet together with 16109 live
B. breve DPC6330 microorganisms daily. A second group received
16109 live B. breve DPC6330 microorganisms, while the third
group received a placebo (15% (w/v) trehalose added as a
cryoprotectant plus 2% (w/v) bovine serum albumin added as an
emulsifier). The treatments were administered by oral gavage for 7
weeks starting at postnatal day (PND) 28. The diet was sterilized
before feeding and contained the following nutrient composition:
crude protein (18.6%), fat (6.2%), crude fiber (3.5%), neutral
detergent fiber (14.7%), and ash (5.3%). The fatty acids present in
the diet included palmitic acid (C16:0, 0.7%), stearic acid (C18:0,
0.2%), oleic acid (C18:1n-9, 1.2%), LA (C18:2n-6, 3.1%), and
ALA (C18:3n-3, 0.3%). Body weight was assessed weekly.
Following 7 weeks on experimental diets, the animals were
sacrificed by decapitation. Liver, prefrontal cortex, and mesenteric
adipose tissue were removed, blotted dry on filter paper, weighed
and flash-frozen immediately in liquid nitrogen. Blood serum was
collected by allowing blood samples to clot for 2 h at 4uC before
centrifuging at 30006 g for 20 min and collecting the serum. All
samples were stored at 280uC until processed.
Preparation and administration of B. breve DPC6330
B. breve DPC6330, which has previously been shown to convert
#80% LA to c9, t11 CLA when grown in 0.5 mg/ml LA in vitro
was stocked at 280uC in 40% (v/v) glycerol in the Teagasc,
Moorepark Food Research Centre culture collection. The genome
sequence of the strain has been elucidated [50]. The strain was
cultured in MRS broth (Difco, Detroit, Mich.) supplemented with
0.05% (w/v) L-cysteine-hydrochloride (mMRS) (98% pure Sigma
Chemical Co., St. Louis, Mo.) under anaerobic (anaerobic jars
with AnaerocultHA gas packs; Merck, Darmstadt, Germany)
conditions at 37uC. When a solid medium was required, 1.5%
(w/v) agar (Oxoid, Hampshire, UK) was added to the mMRS
medium. For use in the rat trials, B. breve DPC6330 was initially
grown in mMRS for 72 h, washed twice in phosphate buffered
saline (PBS) and resuspended at ,161010 cells/ml in 15% (w/v)
trehalose (Sigma). Two hundred ml volumes were freeze-dried
using a 24 h program (freeze temperature 240uC, condenser set
point 260, vacuum set point 1.3361023 mBarr). The number of
B. breve DPC6330 colony forming units (CFU) per gram of freeze
dried powder was determined by serially diluting 1 gram of
powder in maximum recovery diluent (MRD) (Oxoid) and plating
on mMRS agar at 37uC under anaerobic conditions.
Separation Procedure
Rat pups were separated from their mother for 3 hours every
day from post natal day (PND) 2 to 12 as previously described
[25]. From PND 13 until 22, pups were maintained with their
mothers. All animals were weaned on PND 22.
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Colorectal Distension
Each animal was anaesthetized with isoflourane and a latex
balloon, 6 cm in length was inserted into the colon, 1 cm from the
anus. The animals recovered for 10 min prior to colorectal
distension (CRD). The balloon was then connected to a barostat
and the animal placed in an observation chamber. The balloon
was distended from 0–80 mm Hg over an 8 min period. During
this time, the threshold i.e. the pressure at which the animals
displayed their first pain behaviour, as well as the number of pain
behaviours were noted. The frequency of contractions of the
abdominal wall is considered as a reliable marker of visceral
sensitivity [25]. Animals were tested in a random fashion and the
experimenter was blinded to the individual groups.
Lipid extraction and fatty acid analysis
Lipids were extracted using chloroform:methanol (2:1 v/v;
Fisher Scientific, Dublin, Ireland) according to a previously
described method [51]. Fatty acid methyl esters (FAME) were
prepared by adding 10 ml 0.5 N NaOH (Sigma) in methanol to
dry fat for 10 min at 90uC followed by 10 ml 14% (w/v) BF3 in
methanol (Sigma) for 10 min at 90uC (21). FAME were extracted
with hexane (Fisher Scientific), dried with 0.5 g of anhydrous
sodium sulphate (Sigma) for 1 hr and stored at 220uC prior to
gas-liquid chromatography (GLC) analysis. FAME were separated
by GLC (Varian 3800, Varian, Walnut Creek, CA, USA) fitted
with a flame ionization detector, using a Chrompack CP Sil 88
column (Chrompack, Middleton, The Netherlands,
100 m60.25 mm i.d., 0.20 mm film thickness) and Helium as
carrier gas. The column oven was programmed to be held initially
at 80uC for 8 min then increased 8.5uC/min to a final column
temperature of 200uC. The injection volume used was 0.6 ml, with
automatic sample injection on a SPI 1093 splitless on-column
temperature programmable injector. Peaks were integrated using
the Varian Star Chromatography Workstation version 6.0
software and peaks were identified by comparison of retention
times with pure FAME standards (Nu-Chek Prep, Elysian, MN,
USA). The percentage of individual fatty acids was calculated
according to the peak areas relative to the total area (total fatty
acids were set at 100%). All fatty acid results are shown as mean6
standard error of the mean (SEM) g/100 g FAME.
All laboratory animal experimentations were performed ac-
cording to the guidelines for the care and use of laboratory animals
approved by the Department of Health and Children of the Irish
government. This study was approved by the ethics committee of
University College Cork.
Statistical analysis
Results in the text, tables and figures are presented as Mean per
group 6 SEM. To assess if differences between treatment groups
were significant, data were analysed using one-way analysis of
variance (ANOVA) followed by post hoc Tukey’s multiple
comparison tests using GraphPad Prism version 5.0 for Windows
(GraphPad Software, San Diego, CA, USA). Results were
considered significant as follows: * p,0.05, **p,0.01,
***p,0.001. Data were analysed for outliers using Grubb’s test
(GraphPad Software).
Results
There was no significant difference in the rate of weight gain
between the groups (data not shown).
The effect of B. breve DPC633060.5% (w/w) linoleic acid
and 0.5% (w/w) a-linolenic acid on visceral
hypersensitivity
While the MS group fed an un-supplemented diet exhibited the
lowest pain threshold of all six groups included in this study, the
NS rats fed B. breve DPC6330 were the only group which displayed
an increased pain threshold compared to the MS control group
(p,0.05, Figure 1).
The effect of B. breve DPC633060.5% (w/w) linoleic acid
and 0.5% (w/w) a-linolenic acid on the liver fatty acid
composition
Following 7 weeks of dietary treatment, the MS control group
had the lowest DHA content in the liver (Table 1). Administration
of B. breve DPC6330 to MS rats led to significantly increased DHA
content in the liver, compared with the un-supplemented control
group (p,0.01, Table 1). The NS rats receiving B. breve in
combination with LA and ALA had a higher concentration of
DPA in the liver after 7 weeks of feeding compared to the MS and
NS controls (p,0.05 Table 1), with the MS control group having
the lowest amount of DPA in the liver of all the groups (p,0.05).
The mean arachidonic acid content of the liver was significantly
higher in the NS control rats compared to the MS control rats
(p,0.05, Table 1). Indeed, the MS control rats had lowest
concentration of arachidonic acid and highest concentration of
palmitoleic acid in the liver of all the groups. Oral administration
of B. breve DC6330 also led to a significant increase in the
arachidonic acid content of MS rats and a significant decrease in
palmitoleic acid (p,0.05, Table 1). Higher amounts of ALA were
found in the liver of the MS control group compared to NS control
group (p,0.05 Table 1).
Figure 1. The average threshold value (pressure at which the
animal shows the first pain behaviour) of each group.
(* =p,0.05). White columns- Non separated rats fed un-supplement-
ed diet, Chequered columns- Maternally separated fed un-supplement-
ed diet, Horizontal lines- Non separated rats fed Bifidobacterium breve
DPC 6330, Vertical lines- Maternally separated rats fed Bifidobacterium
breve DPC 6330, Upward diagonal lines- Non separated rats fed
Bifidobacterium breve DPC 6330 plus 0.5% linoleic acid and 0.5% a-
linolenic acid, Downward diagonal lines- Maternally separated rats fed
Bifidobacterium breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5%
(w/w) a-linolenic acid.
doi:10.1371/journal.pone.0048159.g001
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The effect of B. breve DPC633060.5% (w/w) linoleic acid
and 0.5% (w/w) a-linolenic acid on the adipose tissue
fatty acid composition
The palmitoleic acid content of the adipose tissue of MS control
rats was the lowest of all six groups after 7 weeks of dietary
treatment. Furthermore, only the NS rats receiving B. breve
DPC6330 had a significantly higher palmitoleic acid content in the
adipose tissue compared with the MS group (p,0.05, Table 2).
The MS control group had significantly lower oleic acid than the
NS control group (p,0.05, Table 2). The MS control group also
exhibited decreased oleic acid content of adipose tissue when
compared with the NS rats receiving B. breve DPC6330, however,
feeding B. breve DPC6330 did not increase oleic acid in NS rats
(Table 2). The MS and NS groups receiving B. breve with LA and
ALA supplementation (groups E and F) exhibited higher
concentrations of ALA (p,0.001) in adipose tissue compared to
un-supplemented or B. breveDPC6330 supplemented rats (Table 2).
The MS control group had significantly higher eicosenoic acid
(C20:1c11) than the NS control group (p,0.05, Table 2).
Administration of B. breve DPC6330 to MS rats decreased
eicosenoic acid (p,0.05, Table 2).
The effect of B. breve DPC633060.5% (w/w) linoleic acid
and 0.5% (w/w) a-linolenic acid on the fatty acid
composition of rat serum
After 7 weeks of dietary treatment, the DHA content of the MS
control group was lowest of all six groups, with a significant
increase in DHA content of the NS control group (p,0.05,
Table 3). The NS rats receiving B. breve (without LA and ALA
supplementation) exhibited an increased serum concentration of
EPA compared to un-supplemented rats (p,0.05, Table 3). The
same effect was not observed in MS rats, however. Maternally
separated animals receiving B. breve DPC6330 in combination with
fatty acid supplementation exhibited significantly increased serum
EPA concentration compared to the B. breve DPC6330 supple-
mented MS group (p,0.001, Table 3). The mean DPA content of
the serum of NS rats was significantly increased following B. breve
DPC6330 supplementation and B. breve DPC6330 supplementa-
tion in combination with LA and ALA (p,0.01 and p,0.05,
respectively, Table 3). Oral administration of B. breve to MS rats
did not result in a change the DPA content of the serum, however,
administration of B. breve DPC6330 in combination with fatty acid
supplementation did significantly increase DPA, compared to the
MS control group (p,0.01, Table 3). The palmitoleic acid content
of the serum of the MS control group was highest of all six groups,
with a significant decrease in palmitoleic acid content of the NS
control group compared to the MS control group (p,0.05,
Table 3).
The effect of B. breve DPC633060.5% (w/w) linoleic acid
and 0.5% (w/w) a-linolenic acid on the fatty acid
composition of rat prefrontal cortex
The palmitoleic acid content of the prefrontal cortex of the MS
control group was highest of all six groups (0.63 6 0.04 g/100 g
FAME), with a significant decrease in palmitoleic acid content of
the B. breve DPC6330 administered MS group (p,0.05, 0.41 6
0.01 g/100 g FAME, Table 4).
Discussion
This study shows that there are differences in arachidonic acid,
DHA, ALA and palmitoleic acid in the tissues of NS and MS rats
and indeed the levels of palmitoleic acid, arachidonic acid and
DHA can be influenced by oral administration of B. breve
DPC6330 in MS rats. The present study supports previous
observations that altering the gut microbiota changes host fat
composition [47,48,49]. Indeed, the strain has previously been
found to alter the palmitoleic acid content in the brain and adipose
tissue, DHA in the liver and adipose tissue, increased propionate
in the caecum and alterations the caecal microbiota in C57BL6/J
mice [49]. It is clear that the strain is metabolically active in the GI
tract, however, no increases in arachidonic acid and DHA were
observed in the liver of NS rats fed B. breve DPC6330.
Interestingly, we have previously seen that feeding B. breve
DPC6330 to MS and NS rats elicited differing responses, however,
Table 1. Fatty acid profile in liver of Non-Maternally Separated rats fed un-supplemented diet (A), Maternally Separated rats fed
un-supplemented diet (B), Non-Maternally Separated rats fed B. breve DPC6330 (C), Maternally Separated rats fed B. breve DPC6330
(D), Non-Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (E),
Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (F) for 7 weeks.
g/100 g FAME Liver
A B C D E F
C16:0 31.9860.48 32.5560.33 31.8460.74 32.5260.36 32.2860.61 31.9260.45
C16:1c9 2.0860.25 d* 2.8360.25 2.2860.23 b* 1.9160.19 2.3060.17 2.1760.17
C18:0 13.6360.36 14.1860.33 13.8360.52 13.1760.30 14.1060.53 14.3660.48
C18:1c9 6.2660.16 6.9360.19 6.4460.18 6.2860.22 6.4660.16 6.3360.14
C18:1t9 2.1560.06 2.5560.10 2.2560.13 2.1360.10 2.3160.42 2.1960.10
C18:2n-6 17.3860.22 17.0660.25 16.7060.43 16.5360.47 16.3260.37 16.4460.28
C18:3n-3 b* 0.30960.01 a* 0.37260.02 0.33060.01 0.32960.01 0.34360.01 0.32860.01
C20:4n-6 b* 14.0660.24 a*,d* 12.7660.32 13.1360.25 b* 14.0260.27 13.4360.21 13.4260.35
C22:5n-3 e* 0.77660.04 e* 0.76260.06 0.90460.06 0.87860.04 a*,b* 1.02560.05 0.93160.04
C22:6n-3 3.2660.14 d**,e* 2.6260.12 2.8960.08 b** 3.4160.21 b* 3.3160.73 3.0960.10
Results are expressed as percentage of total identified fatty acids. Data are Means 6 SEM g/100 g FAME. A, B, C, D, E, F Different superscript letters within a column
indicate significant difference (* = p,0.05, ** = p,0.01, *** = p,0.001). FAME= fatty acid methyl esters. C16:0 palmitic acid; C16:1c9 palmitoleic acid; C18:0 stearic acid;
C18:1c9 oleic acid; C18:2n-6 linoleic acid; C18:3n-3 linolenic acid; C20:4n-6 arachidonic acid; C22:5n-3 docosapentaenoic acid; C22:6n-3 docosahexaenoic acid.
doi:10.1371/journal.pone.0048159.t001
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in that case B. breve DPC6330 altered brain derived neurotrophic
factor (BDNF) in the NS animals, with no effect in MS rats [52].
We suggested that the reason a response was not observed in MS
rats following administration of B. breve DPC6330 was due to a
ceiling effect for the biomarker and perhaps this is the same in
relation to palmitoleic acid, arachidonic acid and DHA for NS rats
fed B. breve DPC6330. B. breve DPC6330 had a greater effect on
fatty acid metabolism in MS animals compared with NS animals.
There were only two instances in this study where feeding B. breve
DPC6330 to the NS rats significantly increased fatty acid content
(EPA and DPA in the serum, both are involved in the pathway for
DHA production and have a number of proposed health benefits
[53]). Recently EPA, rather than DHA, has been identified as the
key v-3 fatty acid in treating depression [54]. EPA was only
detected in measurable amounts in the serum of animals
throughout the study. Administering B. breve DPC6330 to NS rats
Table 2. Fatty acid profile in adipose tissue of Non-Maternally Separated rats fed un-supplemented diet (A), Maternally Separated
rats fed un-supplemented diet (B), Non-Maternally Separated rats fed B. breve DPC6330 (C), Maternally Separated rats fed B. breve
DPC6330 (D), Non-Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (E),
Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (F) for 7 weeks.
g/100 g FAME Adipose Tissue
A B C D E F
C16:0 24.2660.34 23.3360.47 24.3260.54 24.4260.35 23.3660.27 22.7660.49
C16:1c9 3.5160.15 c* 2.7960.20 b* 3.7460.24 3.4460.16 3.2060.20 3.0860.23
C18:0 4.1560.11 4.4060.08 4.0760.09 4.3260.17 4.4560.12 3.9960.04
C18:1c9 b,f*** 25.8060.13 a,c** 24.7760.21 b**,f*** 25.9760.27 f** 25.5260.22 25.1360.20 a***,c**,d** 24.2460.24
C18:1t9 1.7860.06 1.6660.04 1.5660.08 1.6960.06 1.7560.04 1.5860.06
C18:2n-6 35.0260.60 37.4060.78 34.6860.89 35.0460.58 35.9960.69 37.6460.81
C18:3n-3 e***,f*** 2.1060.05 f***, 2.2760.06 e**, f*** 2.1460.06 e**, f*** 2.1560.06 a***,c***,d***,f*** 2.6660.13 a***,b***,c***,d***,e** 3.3160.17
C20:1c11 b* 0.20860.007 a*,d* 0.23260.004 0.21460.005 b* 0.20760.005 0.21360.005 0.21660.004
C20:4n-6 0.4860.04 0.4860.03 0.5460.05 0.5160.04 0.4260.01 0.4660.02
Results are expressed as percentage of total identified fatty acids. Data are Means 6 SEM g/100 g FAME.
A, B, C, D, E, F Different superscript letters within a column indicate significant difference (* = p,0.05, ** = p,0.01, *** = p,0.001). FAME = fatty acid methyl esters. C16:0
palmitic acid; C16:1c9 palmitoleic acid; C18:0 stearic acid; C18:1c9 oleic acid; C18:1t9 elaidic acid; C18:2n-6 linoleic acid; C18:3n-3 linolenic acid; C20:1c11 eicosenoic acid;
C20:4n-6 arachidonic acid.
doi:10.1371/journal.pone.0048159.t002
Table 3. Fatty acid profile in serum of Non-Maternally Separated rats fed un-supplemented diet (A), Maternally Separated rats fed
un-supplemented diet (B), Non-Maternally Separated rats fed B. breve DPC6330 (C), Maternally Separated rats fed B. breve DPC6330
(D), Non-Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (E),
Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (F) for 7 weeks.
g/100 g FAME Serum
A B C D E F
C16:0 22.6160.19 23.4360.26 23.4660.25 22.9760.25 22.9460.20 23.3860.20
C16:1c9 b* 1.1560.08 a* 1.8560.11 1.4560.12 1.2960.12 1.5360.13 1.3960.11
C18:0 11.6860.23 11.2960.28 11.8660.20 11.4560.24 11.2660.26 11.8760.16
C18:1c9 11.0760.22 11.4260.39 10.6860.22 11.7060.25 11.3260.33 10.9860.18
C18:1t9 1.5860.03 1.7960.04 1.7060.05 1.5860.05 1.6960.07 1.6360.04
C18:2n-6 28.6560.31 27.9860.53 27.9360.50 28.3460.48 28.8260.44 28.0860.47
C18:3n-3 1.2660.04 1.3960.03 e* 1.1860.04 1.2660.07 c* 1.4560.06 1.2960.07
C20:3n-6 0.4160.01 0.4460.02 0.4460.01 0.4560.01 0.4160.01 0.4560.02
C20:4n-6 15.3860.36 14.2960.55 15.2260.27 14.5460.46 14.8160.49 14.4260.28
C20:5n-3 c*,f** 0.1960.01 0.2160.01 a*,d* 0.2360.007 c,f*** 0.1860.006 f* 0.2060.008 a**,d***,e 0.2560.02
C22:4n-6 0.2960.02 0.3260.01 0.3360.01 0.3360.01 0.2860.02 0.3060.02
C22:5n-3 c**,e*,f*** 0.34160.01 f** 0.35960.02 a**, d* 0.41460.01 c*,f*** 0.35560.01 a* 0.41260.01 a***,b**, d*** 0.44360.02
C22:6n-3 b* 1.8360.09 a* 1.4260.08 1.6660.12 1.7460.12 1.6060.11 1.7160.07
Results are expressed as percentage of total identified fatty acids. Data are Means 6 SEM g/100 g FAME.
A, B, C, D, E, F Different superscript letters within a column indicate significant difference (* = p,0.05, ** = p,0.01, *** = p,0.001). FAME = fatty acid methyl esters. C16:0
palmitic acid; C16:1c9 palmitoleic acid; C18:0 stearic acid; C18:1c9 oleic acid; C18:1t9 elaidic acid; C18:2n-6 linoleic acid; C18:3n-3 linolenic acid; C20:3n-6 dihomo-c-
linolenic acid; C20:4n-6 arachidonic acid; C20:5n-3 eicosapentaenoic acid; C22:4 adrenic acid; C22:5n-3 docosapentaenoic acid; C22:6n-3 docosahexaenoic acid.
doi:10.1371/journal.pone.0048159.t003
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increased EPA but did not influence EPA in MS rats. Feeding B.
breve DPC6330 plus fatty acid supplementation to NS rats did not
change EPA levels compared to un-supplemented controls, it did
however, increase EPA levels in the serum of MS animals
compared to the MS B. breve DPC6330 fed group. This is another
example of the different responses in NS and MS rats. Feeding B.
breve DPC6330 to MS rats also significantly decreased the amount
of eicosenoic acid (c11) in the adipose tissue, reaching similar levels
as observed in the NS rats.
The mechanism by which B. breve DPC6330 changes fatty acid
composition observed in the present study is uncertain and
remains to be elucidated. Solakivi et al. suggested that decreased
arachidonic acid and DHA in humans with IBS may by due to
reduced intestinal mal-absorption rather than reduced biosynthesis
by desaturases and elongases [41]. However, in the case of B. breve
DPC6330 feeding, perhaps the strain aids in intestinal absorption
of PUFAs or regulates desaturase activity, as has previously been
suggested [47], since probiotic bacteria have been reported to
influence desaturase activity in animal tissues and increase serum
arachidonic acid [55]. Perhaps feeding B. breve DPC6330 to rats
influences corticosterone levels, a stress related hormone involved
in fat metabolism [56]. Previously corticosterone has been
reported to be elevated in MS rats [25,57] and indeed, feeding
probiotics reduced stress induced corticosterone levels [57,58].
Fatty acid supplementation in this study did not influence the
arachidonic acid or DHA contents in rat tissues or serum, it did
however, increase the ALA acid content in the adipose tissue, as
expected. Feeding B. breve DPC6330 in combination with fatty
acid supplementation significantly increased the EPA content in
the serum of MS rats, compared with B. breve DPC6330-fed MS
rats but not the MS control group, while also increasing the DPA
content in MS rats compared with un-supplemented and B. breve
DPC6330-fed animals. It is likely that fatty acid supplementation
had little effect on the fatty acid content of tissues and serum of the
rats due to the fact that the animal diet already contained high
levels of LA and ALA (3.1% (w/w) and 0.3% (w/w), respectively).
Arachidonic acid and DHA are crucial factors in brain
development, neurogenesis and neurotransmission, and also
influence cognitive processes in the brain [59,60,61] and as a
result are incorporated into infant formula [62]. The anti-
inflammatory properties of EPA and DHA and their ability to
decrease proinflammatory cytokines have previously been report-
ed [63,64,65]. It has been suggested that the anti-inflammatory
properties of EPA and DHA are predominantly due to the
replacement of arachidonic acid in cell membranes, resulting in
decreased production of arachidonic acid-derived proinflamma-
tory eicosanoids such as prostaglandin E2 and leukotriene B4 [63].
However, in this study we found the arachidonic acid content of
the liver increased in association with the DHA content in
response to B. breve DPC6330 feeding in the MS animals. This
shows that arachidonic acid is not being replaced, as the content of
both arachidonic acid and DHA are increasing. It has previously
been reported that female human patients with IBS have elevated
levels of plasma arachidonic acid, linked to an increase in
eicosanoid production [39]. Furthermore, an increase in plasma
arachidonic acid has been observed in MS rats when compared to
NS rats, as well as increases and decreases in stearic and oleic
acids, respectively [29]. More recently, conflicting results have
found the levels of arachidonic acid and DHA to be lower in the
serum of IBS patients, varying results were not attributed to
gender differences [41]. Similarly, we found increased liver
arachidonic acid and serum DHA levels in NS rats compared
with MS rats. The differences maybe due to differences in samples
assayed (serum v plasma).
It has previously been reported that probiotic administration
decreased visceral hypersensitivity [66] and changes in the species
and numbers of the faecal microbiota have been reported in IBS
patients [67]. Significant differences in the fatty acid content of
tissues were only detected for the palmitoleic and elaidic acid of
the adipose tissue of the MS control and B. breve DPC6330 fed NS
groups, the groups with the greatest differences in pain observed
thresholds. A significant difference was also recorded in the
Table 4. Fatty acid profile in prefrontal cortex of Non-Maternally Separated rats fed un-supplemented diet (A), Maternally
Separated rats fed un-supplemented diet (B), Non-Maternally Separated rats fed B. breve DPC6330 (C), Maternally Separated rats
fed B. breve DPC6330 (D), Non-Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-
linolenic acid (E), Maternally Separated rats fed B. breve DPC6330 plus 0.5% (w/w) linoleic acid and 0.5% (w/w) a-linolenic acid (F)
for 7 weeks.
g/100 g FAME Prefrontal Cortex
A B C D E F
C16:0 26.8960.45 25.2460.46 25.5460.52 26.2260.33 25.1160.50 25.1460.42
C16:1c9 0.5360.03 d* 0.6360.04 0.5360.03 b* 0.4160.01 0.5460.05 0.5560.04
C18:0 23.7260.20 23.4460.20 23.5060.30 23.4260.14 23.3760.10 23.2860.07
C18:1c9 14.1660.14 13.9560.11 14.0160.21 14.0460.17 14.0160.17 14.1560.20
C18:1t9 2.7960.06 2.9760.06 2.9660.05 2.8660.04 2.9160.05 2.9560.05
C18:2n-6 0.8960.08 0.7960.07 0.8760.04 0.8760.05 0.8560.04 0.9760.05
C20:4n-6 10.7560.22 11.2860.25 11.3460.17 11.0860.11 11.4660.18 11.5460.11
C22:4 3.4760.08 3.6360.08 3.5660.08 3.5660.04 3.5760.07 3.5760.04
C24:1 1.2460.04 1.3760.06 1.2960.05 1.2260.04 1.2160.05 1.2860.04
C22:6n-3 13.5760.31 13.7560.26 13.7260.25 14.2360.29 14.3760.27 14.2060.16
Results are expressed as percentage of total identified fatty acids. Data are Means 6 SEM g/100 g FAME.
A, B, C, D, E, F Different superscript letters within a column indicate significant difference (* = p,0.05, ** = p,0.01, *** = p,0.001). FAME = fatty acid methyl esters. C16:0
palmitic acid; C16:1c9 palmitoleic acid; C18:0 stearic acid; C18:1c9 oleic acid; C18:1t9 elaidic acid; C18:2n-6 linoleic acid; C20:4n-6 arachidonic acid; C22:4 adrenic acid;
C24:1 nervonic acid; C22:5n-3 docosapentaenoic acid; C22:6n-3 docosahexaenoic acid.
doi:10.1371/journal.pone.0048159.t004
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palmitoleic acid contents in the serum of NS and MS controls and
in the liver and prefrontal cortex of MS control and MS rats fed B.
breve DPC6330. An increase in palmitoleic acid (not significant) has
previously been seen in IBS patients compared to controls [41].
Interestingly, palmitoleic acid has recently been described as a
‘‘lipokine’’, i.e. an adipose tissue-derived lipid hormone which links
adipose tissue to systemic metabolism [68]. It has been linked with
suppression of adipocyte cytokine expression, promotion of
pancreatic b-cell proliferation, enhancement of skeletal muscle
glucose uptake and stimulation of adipocyte peroxisome prolif-
erator–activated receptor-c transcriptional activity in animal
studies [68,69,70,71], however, its effects on human health are
still unclear [72]. Clearly, there are differences in the serum levels
of palmitoleic acid in MS and NS rats and perhaps it plays a role
in IBS, however, more research is needed to confirm this. This
ability of bifidobacteria to influence the fatty acid content in MS
rats is another example of a potential therapeutic application of
the genus to treat IBS and depression, a list which already includes
normalization of the immune response, reversal of behaviour
deficits and the restoration of basal noradrenaline concentrations
[30].
In conclusion, our results demonstrate that 1) there are
differences in arachidonic acid, DHA, ALA and palmitoleic acid
in the tissues of NS and MS rats, 2) palmitoleic acid, arachidonic
acid and DHA can be influenced by oral administration of B. breve
DPC6330 in MS rats, 3) palmitoleic acid plays a role in maternally
separated rats, however, further studies are required to draw
conclusions about the role of this fatty acid in IBS patients.
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